Afinitor plus Somatuline significantly improved PFS in GEP-NETs compared to Afinitor monotherapy, with median PFS of 29.7 vs. 11.5 months. The combination therapy showed a higher objective response ...
ITM-11 significantly improved progression-free survival over everolimus in GEP-NETs patients, marking a first for targeted radiopharmaceutical therapy in a phase 3 trial. The COMPETE trial included ...
Sanofi and Orana Med’s radiopharmaceutical candidate has met all its primary endpoints in a Phase II trial, meaning the former’s €320m bet on the therapy looks to be paying off. In the ongoing ...
SAN FRANCISCO -- Progression-free survival (PFS) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) more than doubled with the addition of the somatostatin analog (SSA) lanreotide (Somatuline ...
When Is Enough Enough? Personalized Decision Making in Long-Term Cancer Care This review aims to understand the perspectives of patients with well-differentiated GEP-NETs on considering radioligand ...
The COMPETE trial (NCT03049189) evaluated (177) Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, ...
Phase I/II, first-in-human study of yttrium-90 carbon microspheres in patients with unresectable hepatocellular carcinoma: Safety and early efficacy profiles. This is an ASCO Meeting Abstract from the ...
Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026 Molecular Targeting Technologies, Inc. (MTTI) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results